Payment overview · 2025
General Payments
$256.56
12 reported records · 7 companies
Healthcare provider profile · identity verified
Michelle Lynn Kaplan, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, OR · NPI 1396797916
Verified facts
What the public records show
CMS Open Payments records show Michelle Lynn Kaplan, MD received $256.56 in general payments during 2025 across 12 reported records.
Exact Sciences Corporation accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $60.40 | 23.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.84 | 20.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.44 | 17.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.67 | 13.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.98 | 12.5% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $20.00 | 7.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.23 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.58 | 10 |
| Education | $31.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.44 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.67 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.98 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.82 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $29.68 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 99 |
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 71 |
| Lisinopril | Lisinopril | 255 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 233 | 66 |
| Alendronate Sodium | Alendronate Sodium | 197 | 52 |
| Furosemide | Furosemide | 170 | 36 |
| Losartan Potassium | Losartan Potassium | 152 | 42 |
| Trazodone Hcl | Trazodone Hcl | 149 | 28 |
| Omeprazole | Omeprazole | 144 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 37 |
| Gabapentin | Gabapentin | 126 | 36 |
| Metformin Hcl Er | Metformin Hcl | 125 | 30 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 114 | 12 |
| Metformin Hcl | Metformin Hcl | 112 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 24 |
| Ozempic | Semaglutide | 101 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 19 |
| Eliquis | Apixaban | 90 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 37 |
| Meloxicam | Meloxicam | 85 | 31 |
| Simvastatin | Simvastatin | 73 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 24 |
| Potassium Chloride | Potassium Chloride | 65 | 18 |
| Jardiance | Empagliflozin | 63 | 17 |
| Bupropion Xl | Bupropion Hcl | 62 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 15 |
| Fenofibrate | Fenofibrate | 56 | 15 |
| Allopurinol | Allopurinol | 54 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 19 |
| Carvedilol | Carvedilol | 47 | 16 |
| Sertraline Hcl | Sertraline Hcl | 45 | 12 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 13 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 11 |
| Celecoxib | Celecoxib | 35 | 15 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 12 |
| Nystatin | Nystatin | 29 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 11 |
| Baclofen | Baclofen | 25 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.56 · 12 records | Exact Sciences Corporation | APTIMA, BREZTRI, Cologuard Collection Kit, GEMTESA, JARDIANCE, MAVYRET, QULIPTA, REXULTI, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error